Mosaic Immunoengineering INC

Mosaic ImmunoEngineering and Oncotelic Therapeutics have extended the deadline for their potential acquisition agreement to June 30, 2025, to allow more time for due diligence and finalizing the deal.

Carlton Johnson has resigned from the Board of Directors of Mosaic ImmunoEngineering, Inc., effective immediately, also stepping down from all board committees.

Mosaic ImmunoEngineering's CFO, Paul Lytle, will transition to a part-time role effective June 1, 2024, as the company seeks a $4 million capital raise.

Mosaic ImmunoEngineering has changed its independent registered public accounting firm from KMJ Corbin & Company LLP to Rose, Snyder & Jacobs LLP, effective May 22, 2024.

Mosaic ImmunoEngineering has agreed to acquire clinical-stage necroptosis cancer therapy assets and AI technology from Oncotelic Therapeutics in a deal involving stock and potential milestone payments.

Mosaic ImmunoEngineering reports the passing of independent director Gloria Felcyn, who served on the board since 2002.

Mosaic ImmunoEngineering, Inc. reported its first-quarter 2026 financial results, highlighting a significant decrease in cash and cash equivalents and continued operational losses, underscoring the critical need for future capital raises.

Mosaic ImmunoEngineering, a development-stage biotech, reported significant cash depletion and a going concern warning, with a key acquisition agreement expiring and multiple board resignations.

Mosaic ImmunoEngineering, a development-stage biotech, reported significant financial challenges, including a going concern warning and the expiration of a key acquisition agreement.

Mosaic ImmunoEngineering's Q1 2025 report reveals a net loss of $181,320 and raises concerns about the company's ability to continue as a going concern due to limited cash and the need for additional financing.

Mosaic ImmunoEngineering's Q3 2024 report reveals ongoing losses and significant financial challenges, raising substantial doubt about the company's ability to continue as a going concern.

Mosaic ImmunoEngineering faces significant financial challenges and is exploring a potential acquisition to bolster its pipeline.

Mosaic ImmunoEngineering's 10-K filing reveals significant going concern risks due to insufficient working capital and ongoing discussions for a potential acquisition of Oncotelic's technologies, which could lead to substantial dilution.

Mosaic ImmunoEngineering's 10-K filing reveals substantial doubt about its ability to continue as a going concern, despite efforts to acquire new technologies from Oncotelic Therapeutics.

Mosaic ImmunoEngineering reports a net loss of $1.008 million for 2023 and faces substantial doubt about its ability to continue as a going concern due to insufficient working capital and the termination of a key license agreement.